COX-2 limits prostanoid production in activated HUVECs and is a source of PGH2 for transcellular metabolism to PGE2 by tumor cells
The relationship between RBP and tamoxifen resistance is related to the PI3K/AKT pathway
An exogenous IGF-1R agonist introduced at the endpoint is not sensed by that feedback loop in the same way and does not switch itself off through this mechanism
During compounding, ingredients may be combined, mixed, or altered
Medicare Obesity Coverage Expansion (Regulatory): The Centers for Medicare & Medicaid Services (CMS) announced that beginning in April 2026, Medicare will cover GLP-1 medications for beneficiaries with obesity and qualifying comorbidities via the BALANCE Model and Section 402 demonstrations, marking a reversal of the long-standing statutory ban on weight-loss drug coverage
Dillon EL, Sheffield-Moore M, Paddon-Jones D, Gilkison C, Sanford AP, Casperson SL, et al